683 Capital Management’s Fortress Biotech FBIO Stock Holding History

683 Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,333	Closed	-$635K	–	197
2020 Q4	$635K	Hold	13,333	–	–	0.03%	131
2020 Q3	$808K	Hold	13,333	–	–	0.06%	101
2020 Q2	$536K	Hold	13,333	–	–	0.04%	105
2020 Q1	$379K	Sell	13,333 -5,191	-28%	-$172K	0.04%	105
2019 Q4	$715K	Buy	18,524 +5,191	+39%	+$133K	0.08%	75
2019 Q3	$283K	Buy	+13,333	New	+$314K	0.03%	109

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

683 Capital Management's FBIO Position: Q1 2021 in Review

683 Capital Management sold out of Fortress Biotech (FBIO) in Q1 2021, closing a stake of 13,333 shares — an estimated $635K sold.

683 Capital Management first reported a position in FBIO in Q3 2019 and held it in 6 quarters. The position peaked at $808K in Q3 2020. 85 funds tracked by Wall St. Rank hold FBIO as of Q1 2021.

683 Capital Management reported no remaining Fortress Biotech position as of Q1 2021 after selling out during the quarter.
683 Capital Management sold 13,333 Fortress Biotech shares in Q1 2021, an estimated $635K.
683 Capital Management first reported a position in Fortress Biotech in Q3 2019 and held it in 6 quarters.
683 Capital Management's Fortress Biotech position peaked at $808K in Q3 2020.
85 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2021.

Based on 683 Capital Management's 13F filing for Q1 2021, filed 17 May 2021.